Thomas B. Tomasi Jr., who led Roswell Park Comprehensive Cancer Center as president and CEO from 1986 to 1996, died March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.
A team of researchers at Roswell Park Comprehensive Cancer Center led by Dhyan Chandra has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer.
Michael Wong joined Roswell Park Comprehensive Cancer Center as the center’s first physician-in-chief.
A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.
Rep. Tim Kennedy (NY-D) announced $7,731,872 in new federal funding for Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of NIH’s Research Facilities Construction Grants.
Thomas Schwaab was named Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research institute.
Roswell Park Comprehensive Cancer Center has earned the highest—”exceptional”—rating from NCI as part of renewal of the grant the institution has held since 1972.
Roswell Park Comprehensive Cancer Center will open a $98 million cell and gene therapy manufacturing facility. It will be the first cell and gene therapy hub in New York.
A study demonstrated that exercise may have the power to strengthen the immune system in patients with multiple myeloma.
Crystal Rodriguez-Dabney was named chief diversity officer and senior vice president, a senior leadership position with direct influence on initiatives across the organization, at Roswell Park Comprehensive Cancer Center.
